Tara M. Fisher

Capital Markets

• Represented Cyteir Therapeutics, a clinical-stage oncology company, in its $133 million IPO. 
• Represented the lead underwriters in the $6.7 billion secondary offering of Regeneron common stock.
• Represented the lead underwriters in the $550 million IPO and concurrent $250 million tangible equity unit offering for Change Healthcare, an independent health care technology platform
• Represented the lead underwriters in the $1.7 billion Elanco Animal Health IPO and the dealer managers in the $8.6 billion exchange of Elanco stock for Lilly stock.
• Represented the lead underwriters in the $725 million common stock offering and concurrent $550 million tangible equity unit offering for Elanco Animal Health to finance the Bayer Animal Health business acquisition.
• Represented TransMedics Group, Inc., a medical technology company focused on transforming organ transplant therapy for end-stage organ failure patients, in its $105 million IPO and $70 million follow-on offering. 
• Represented PQ Group Holdings Inc., a provider of performance chemicals, catalysts, and specialty glass materials and a portfolio company of CCMP, in its $500 million IPO.
• Represented Wright Medical Group, Inc., a global orthopedic medical device company, in connection with its convertible note offering and convertible note hedge and warrant transactions.
• Represented The TJX Companies, Inc., the leading off-price retailer of apparel and home fashions in the U.S. and worldwide, in its $500 million, $750 million, $1 billion and $4 billion registered note offerings.
• Represented the lead underwriters in the $325 million IPO of Wayfair Inc., one of the world’s largest online destinations for the home.
• Represented United Surgical Partners, Inc., an operator of ambulatory surgery and short-stay medical facilities and a portfolio company of Welsh Carson Anderson & Stowe, in its offering of senior secured notes, and a related recapitalization transaction and spinoff.
• Represented a leading American clothing retailer in an exchange offer for its outstanding senior notes, issued in connection with its acquisition by a global private equity firm.
• Represented the lead underwriters in initial public offerings, follow-on equity or convertible notes offerings for issuers such as Auxilium Pharmaceuticals, Lexicon Pharmaceuticals, Regeneron Pharmaceuticals, TherapeuticsMD and Zafgen.

Mergers & Acquisitions

• Represented CIRCOR in its defense of an unsolicited bid and in a proxy contest with an activist investor.
• Represented Pfizer in connection with its $14 billion acquisition of Medivation, a commercial-stage oncology company.
• Represented Medtronic in connection with its $1.3 billion acquisition of HeartWare International, a heart pump manufacturer.
• Represented Shire plc in its $32 billion combination with Baxalta Incorporated, a business spun out of Baxter International, for a combination of cash and stock
• Represented Shire plc its acquisition of Dyax Corp. for $5.9 billion in cash plus contingent value rights.
• Represented The TJX Companies, Inc., the leading off-price retailer of apparel and home fashions in the U.S. and worldwide, in its acquisition of Sierra Trading Post, Inc., an off-price Internet retailer.
• Represented Maple Leaf Foods, Inc. in its $140 million acquisition of Lightlife Foods, Inc., a leading manufacturer and brand of refrigerated plant-based protein foods in the U.S.
• Represented The Strategic Alternatives Special Committee for Market Basket, a chain of discount supermarkets in the northeast, in its $1.5 billion sale.
• Represented Cubist Pharmaceuticals, Inc. in its acquisition of an option to acquire Adynxx, a privately held, clinical-stage pharmaceutical company focused on developing novel analgesic therapies.
• Represented Pfizer in its acquisition of Excaliard Pharmaceuticals, a biopharmaceutical company focused on the development of novel drugs for the treatment of skin scarring.
• Represented Wright Medical Group, Inc. in the sale of its $290 million OrthoRecon business to Hong Kong-based MicroPort Scientific Corporation.
• Represented Novavax, Inc., a clinical-stage vaccine company, in its acquisition of a Czech Republic company Praha Vaccines a.s., a part of the Cyrus Poonawalla Group, and in a cross-border tender offer for the outstanding shares of Isconova, a Sweden-based public vaccine adjuvant company.